

Supplementary data

Supplementary table 3: Review of patients with metastatic PPGL with MAX and TMEM127 mutation

S. no. (Ref.)	Age (Year)/ Gender (M/F)	Pituitary adenoma	Nucleotide change	Pheochromocytoma				Metastasis			
				HT N	Biochemistry (xUNL) 1.PFMN 2.PFNMN 3.UNE	Site (B/L/ Right/ Left)	Size (cm)	Site	Nuclear scan 1. ¹³¹ MIBG scan, 2. FDG 3. DOTA	Treatment	Outcome at last FU Death (Yes/No)
MAX											
1.(1)	51/M		-	Yes	2: 15, 3: 15	Right	-	Bones, Lymph nodes	3: Bones, Lymph nodes	PRRT	-
2.(1)	64/F	Prolactinoma	-	-	Normal	B/L	-	Lymph nodes	3: Lymph nodes	-	-
3.(2)	47/M	-	-	Yes		B/L	-	Lymph node	-	Surgery	No
4.(3)	45/F	-	c.C97>T	Yes	1: 0.9,2:10.4	Left	10	Lymph node	-	Surgery	-
5.(4)	33/M	Acromegaly	-	Yes	Elevated	B/L	4.2	-	-	-	Yes
6.(5)	18/F	-	c.244C>T	-	-	U/L	-	-	-	-	-
7.(5)	40/F	-	c.295p1G>T	-	-	B/L	-	-	-	-	-
8.(6)	32/M	-	c.295+1G>A	-	-	B/L	-	-	-	-	-
9.(6)	46/F	-	c.1A>G	-	-	B/L	-	-	-	-	-
10.(6)	26/F	-	c.67A>G	-	-	U/L	-	-	-	-	-
11.(7)	48/F	-	c.97C>T	-	-	-	10	-	-	-	-
12.(7)	22/F	-	c.97C>T	-	-	-	7	-	-	-	-
TMEM127											
1.(8)	59/F	-	c.419G>A	-	-	B/L	-	Bone	-	-	-
2.(9)	51/F	-	c.464T>A	-	-	B/L	-	-	-	-	-
3.(10)	35/M	-	c.154G>T	-	-	PGL*	-	-	-	-	-
4.(9)	-	-	-	-	-	-	-	-	-	-	-
5.(9)	-	-	-	-	-	-	-	-	-	-	-

B/L –Bilateral, DOTA- ⁶⁸Ga-DOTATATE PET CT scan, F- Female, FDG- ¹⁸fluorodeoxyglucose PET CT scan, FU- Follow up, HTN- Hypertension, M- Male, MIBG- ¹³¹Metaiodobenzylguanidine, PFMN- Plasma free metanephrins, PFNMN- Plasma free normetanephrins, Ref- References, UNE- 24 hours urinary norepinephrines, xUNL- times the upper normal limit.

- Data not available

References:

- Seabrook AJ, Harris JE, Velosa SB, Kim E, McInerney-Leo AM, Dwight T, Hockings JI, Hockings NG, Kirk J, Leo PJ, *et al.* Multiple Endocrine Tumors Associated with Germline MAX Mutations: Multiple Endocrine Neoplasia Type 5? *The Journal of Clinical Endocrinology and Metabolism* 2021 **106** 1163–1182. (<https://doi.org/10.1210/clinem/dgaa957>)
- Korpershoek E, Koffy D, Eussen BH, Oudijk L, Papathomas TG, Nederveen FH van, Belt EJT, Franssen GJH, Restuccia DFJ, Krol NMG, *et al.* Complex MAX Rearrangement in a Family With Malignant Pheochromocytoma, Renal Oncocytoma, and Erythrocytosis. *The Journal of Clinical Endocrinology and Metabolism* 2016 **101** 453–460. (<https://doi.org/10.1210/jc.2015-2592>)
- Chang X, Li Z, Ma X, Cui Y, Chen S & Tong A. A Novel Phenotype of Germline Pathogenic Variants in MAX: Concurrence of Pheochromocytoma and Ganglioneuroma in a Chinese Family and Literature Review. *Frontiers in Endocrinology* 2020 **11** 558. (<https://doi.org/10.3389/fendo.2020.00558>)
- Daly AF, Castermans E, Oudijk L, Guitelman MA, Beckers P, Potorac I, Neggers SJM, Sacre N, Lely AJ van der, Bours V, *et al.* Pheochromocytomas and pituitary adenomas in three patients with MAX exon deletions. *Endocrine-Related Cancer* 2018 **25** L37–L42. (<https://doi.org/10.1530/ERC-18-0065>)
- Burnichon N, Cascón A, Schiavi F, Morales NP, Comino-Méndez I, Abermil N, Inglada-Pérez L, Cubas AA de, Amar L, Barontini M, *et al.* MAX mutations cause hereditary and sporadic pheochromocytoma and paraganglioma. *Clinical Cancer Research: An Official Journal of the American Association for Cancer Research* 2012 **18** 2828–2837. (<https://doi.org/10.1158/1078-0432.CCR-12-0160>)
- Comino-Méndez I, Gracia-Aznárez FJ, Schiavi F, Landa I, Leandro-García LJ, Letón R, Honrado E, Ramos-Medina R, Caronia D, Pita G, *et al.* Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma. *Nature Genetics* 2011 **43** 663–667. (<https://doi.org/10.1038/ng.861>)
- Ma X, Li M, Tong A, Wang F, Cui Y, Zhang X, Zhang Y, Chen S & Li Y. Genetic and Clinical Profiles of Pheochromocytoma and Paraganglioma: A Single Center Study. *Frontiers in Endocrinology* 2020 **11** 574662. (<https://doi.org/10.3389/fendo.2020.574662>)
- Yao L, Schiavi F, Cascon A, Qin Y, Inglada-Pérez L, King EE, Toledo RA, Ercolino T, Rapizzi E, Ricketts CJ, *et al.* Spectrum and prevalence of FP/TMEM127 gene mutations in pheochromocytomas and paragangliomas. *JAMA* 2010 **304** 2611–2619. (<https://doi.org/10.1001/jama.2010.1830>)
- Bausch B, Schiavi F, Ni Y, Welander J, Patocs A, Ngeow J, Wellner U, Malinoc A, Taschin E, Barbon G, *et al.* Clinical Characterization of the Pheochromocytoma and Paraganglioma Susceptibility Genes SDHA, TMEM127, MAX, and SDHAF2 for Gene-Informed Prevention. *JAMA oncology* 2017 **3** 1204–1212. (<https://doi.org/10.1001/jamaoncol.2017.0223>)
- Hamidi O, Young WF, Iñiguez-Ariza NM, Kittah NE, Gruber L, Bancos C, Tamhane S & Bancos I. Malignant Pheochromocytoma and Paraganglioma: 272 Patients Over 55 Years. *The Journal of Clinical Endocrinology and Metabolism* 2017 **102** 3296–3305. (<https://doi.org/10.1210/jc.2017-00992>)

